m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02577)
Name
ML323
Synonyms
ML 323; ML-323
    Click to Show/Hide
Status
Preclinical
Structure
Formula
C23H24N6
InChI
1S/C23H24N6/c1-16(2)20-6-4-5-7-21(20)23-24-14-17(3)22(27-23)25-15-18-8-10-19(11-9-18)29-13-12-26-28-29/h4-14,16H,15H2,1-3H3,(H,24,25,27)
InChIKey
VUIRVWPJNKZOSS-UHFFFAOYSA-N
PubChem CID
60167849
TTD Drug ID
D0M5FO
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Deubiquitinating enzyme 1 (USP1)
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Deubiquitinating enzyme 1 (USP1) is a therapeutic target for ML323. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of ML323 through regulating the expression of Deubiquitinating enzyme 1 (USP1). [1], [2]
References
Ref 1 ALKBH5-mediated m6A-demethylation of USP1 regulated T-cell acute lymphoblastic leukemia cell glucocorticoid resistance by Aurora B. Mol Carcinog. 2021 Sep;60(9):644-657. doi: 10.1002/mc.23330. Epub 2021 Jun 25.
Ref 2 Chemogenomic identification of Ref-1/AP-1 as a therapeutic target for asthma. Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1169-73. doi: 10.1073/pnas.0437889100. Epub 2003 Jan 24.